A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma
Peter Martin(Northwestern University), Leandro Cerchietti(Cornell University), John P. Leonard(New York University), John L. Reagan(Vanderbilt University), María V. Revuelta(Cornell University), Nancy L. Bartlett(Washington University in St. Louis), Julio C. Chávez(Moffitt Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Merry Zhai, Lei Zhang(Hubei University of Medicine), Sonali M. Smith(University of Chicago), Chengqing Wu(Bristol-Myers Squibb (United States)), Ildefonso Ismael Rodriguez Rivera(Texas Oncology)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k